PROLOR Biotech to Present at 2012 Citi Global Health Care Conference

^{Published on 2012-02-22 04:46:23 - Market Wire}
 

PROLOR Biotech to Present at 2012 Citi Global Health Care Conference -- NES-ZIONA, Israel, Feb. 22, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about PBTH

NES-ZIONA, Israel, Feb. 22, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: [ PBTH ]), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 2012 Citi Global Health Care Conference, being held at the Waldorf Astoria Hotel in New York City.  The presentation is scheduled for February 29, 2012 at 11:30 am ET.

A live webcast of the company's presentation will be available at the Investors section of PROLOR's website at [ www.prolor-biotech.com/?CategoryID=215 ], or at [ http://www.veracast.com/webcasts/citigroup/healthcare2012/53308644.cfm ]. An audio replay of the presentation will be available on the PROLOR website approximately one hour after the presentation and will be archived for at least 30 days.

For more information about the 2012 Citi Global Health Care Conference, visit [ https://www.citievents.com/Metron/forms/MeetingFormFiller.aspx?id=399f0110-1028-4b6b-973f-1512bb7328a9 ].

ABOUT PROLOR 
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, as well as agents for atherosclerosis and rheumatoid arthritis, which are all in preclinical development.  For more information, visit [ www.prolor-biotech.com ]

SOURCE PROLOR Biotech, Inc.

RELATED LINKS
[ http://www.prolor-biotech.com ]